Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-23

Study Completion Date

2022-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this trial is to assess the safety of ST266 given by non-invasive intranasal trans-cribriform delivery to glaucoma suspect subjects with ocular hypertension, optic nerve cupping, or family history of glaucoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma

NCT00443924

Ocular Hypertension Open Angle Glaucoma

COMPLETED PHASE1

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691

Open-angle Glaucoma Ocular Hypertension

COMPLETED PHASE2

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

NCT03960866

Open Angle Glaucoma Ocular Hypertension

COMPLETED PHASE2

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

NCT00069719

Open-Angle Glaucoma Ocular Hypertension

COMPLETED PHASE2

A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

NCT02003534

Glaucoma, Open-Angle Ocular Hypertension

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical trial is a dose escalating design in three (3) cohorts. In the first cohort, subjects will be treated with ST266 delivered using a non-invasive trans-cribriform intranasal delivery device daily for 14 days, in alternating single nostrils. If there are no SAEs and no pattern of concern in the AE's, the Investigator may proceed to the second cohort. In Cohort Two, subjects will be administered ST266 to each nostril daily for 14 days. As with the first cohort, if there are no safety concerns, the investigator may move on to the third cohort. In Cohort Three, subjects will be administered ST266 to each nostril daily for 28 days. All subjects will be followed for 12 months after the last dose of study drug. ST266 will be administered by a health care professional trained to deliver ST266 intranasally. No efficacy data will be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

This clinical trial is a dose escalating design in three (3) cohorts of three (3) subjects per Cohort. In the first cohort, subjects will be administered ST266, delivered intranasally, at a dose of two hundred microliters (200 µL) daily for 14 days, in alternating single nostrils. After 14 daily treatments there is a seven (7)-day follow-up period. If there are no SAEs and no pattern of concern in the AE's, the Investigator may proceed to the second cohort of three (3) subjects. In Cohort Two, three (3) subjects will be administered 200 µL to each nostril daily (400 µL total per day) for 14 days. There will be a seven (7)-day follow-up. Like Cohort One, if there are no safety concerns, the investigator may move on to the third cohort of three (3) subjects. In Cohort Three, three (3) subjects will be administered 200 µL to each nostril daily (400 µL total per day) for 28 days.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort One

Three (3) subjects, ST266 200 µL administered by trans-cribriform intranasal device once a day for 14 days using alternating sides (nostrils) with a follow-up visit at seven (7) days following End of Treatment (EOT), a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.

Group Type EXPERIMENTAL

ST266 via Intranasal Delivery

Intervention Type COMBINATION_PRODUCT

ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.

Cohort Two

Three (3) subjects, ST266 400 µL administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 14 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.

Group Type EXPERIMENTAL

ST266 via Intranasal Delivery

Intervention Type COMBINATION_PRODUCT

ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.

Cohort Three

Three (3) subjects, 400 µL ST266 administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 28 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.

Group Type EXPERIMENTAL

ST266 via Intranasal Delivery

Intervention Type COMBINATION_PRODUCT

ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ST266 via Intranasal Delivery

ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed Informed Consent Form and HIPAA (Health Insurance Portability and Accountability Act) document.
2. Male or Female, Ages 20-75 years.
3. Must be clinically followed as a glaucoma suspect without evidence of glaucomatous damage.
4. Must have one of the following: 1) IOP ≤ 28 mmHg and at least one (1) IOP measurement \> 21 mmHg, or 2) physiologic cupping of the optic nerve, or 3) a family history of glaucoma.
5. Two (2) normal visual fields (VF) both Swedish Interactive Threshold Algorithm - Short-wavelength Automated Perimetry (SITA-SWAP) and 24-2 VF prior to subject enrollment at the Baseline Visit.
6. Two (2) normal Ocular Coherence Tomography (OCT) (of macula and nerve fiber layer) prior to subject enrollment at the Baseline Visit.
7. Gonioscopy open to at least scleral spur with normal iris configuration.
8. Normal baseline neuro-cognitive testing.
9. Normal baseline Magnetic Resonance Imaging (MRI), including expected age-related changes, performed with and without contrast.
10. Cohort Three group only: Baseline Lumbar Puncture within normal limits.

Exclusion Criteria

1. Females of Child Bearing Potential (FOCBP) who are pregnant or lactating or who will not abstain from sexual activity for 14 days prior to Visit 1, and willing to remain so through 30 days following completion of the subject's first menstrual cycle following the End of Treatment (EOT) Visit. Alternatively, a WOCBP who will not remain abstinent must have been using one of the following acceptable methods of birth control for the times specified:

* IUD in place for at least three (3) months prior to Visit 1 until completion of the subject's first menstrual cycle following the EOT Visit.
* Barrier method (condom or diaphragm) with spermicide for at least three (3) months prior to Visit 1 through completion of the subject's first menstrual cycle following the EOT Visit.
* Stable hormonal contraceptive for at least three (3) months prior to Visit 1 through completion of the subject's first menstrual cycle following the EOT Visit. NOTE: For Depo-Provera injection contraceptives, the statement regarding first menstrual cycle following administration of the study product is not applicable as females receiving this form of contraception will not have menses.
* In a monogamous relationship with a surgically sterilized (i.e., vasectomized) partner at least six (6) months prior to Visit 1.
* Have undergone one of the following sterilization procedures at least six (6) months prior to Visit 1: Bilateral tubal ligation, Hysterectomy, Hysterectomy with unilateral or bilateral oophorectomy, Bilateral oophorectomy.
2. Unwillingness to submit a urine pregnancy test at screening if of childbearing potential.
3. Male subjects who refuse to use one of the following birth control methods:

* Abstinence from the time of consent and through the duration of their participation in the protocol
* Barrier method (condom or diaphragm) with spermicide from time of consent through the duration of their participation in the protocol
* Surgical sterilization (vasectomy) at least 6 months prior to consent.
4. IOP greater than 29 mmHg in either eye.
5. Patients with high risk factors of ocular hypertension, such as thin central corneas, as identified by the Principal Investigator who may benefit from earlier treatment will be excluded.
6. Evidence of Angle closure.
7. Recent laser or incisional glaucoma surgery.
8. Subjects who are currently taking glaucoma medications. Subject who can safely stop taking these medications during washout period (4-6 weeks) may be considered.
9. Intranasal polyp or any head and/or neck neoplasm.
10. History of or evidence on physical examination including endoscopy of sinus or nasal pathology, nasal passage obstruction, chronic sinus infections, or severe seasonal allergies.
11. Currently using medications given intranasally.
12. Subject is taking any anticoagulant medication such as heparin, low molecular weight heparin, Coumadin, or antiplatelet agents including low dose aspirin.
13. History of stroke or Trans-Ischemic Attack (TIA) within the past five (5) years.
14. Neuro-cognitively impaired as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
15. Subjects who have participated in an investigational product trial within the past 30 days.
16. Subjects who refuse any part of the protocol assessments.

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No